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1. Introduction
Advances in neonatal intensive care have dramatically improved the
survival rate for extremely low birth weight (ELBW, < 1000 g) infants,
but long-term follow-up studies have shown a high risk of neurodeve-
lopmental disabilities, cognitive dysfunction and emotional/beha-
vioural problems [1–4]. Even in children without obvious neurological
deficits, subtle abnormalities, such as lower cognitive test scores and
poorer academic performance, have been reported compared to normal
birth weight controls [5,6]. Areas of cognitive functioning that are
particularly affected by ELBW include attention and executive functions
[7–9], perceptual-motor abilities and visuospatial processing [10,11].
The underlying pathology is termed encephalopathy of prematurity, a
combination of white matter damage and neuronal/axonal disease that
results in the modification of key developmental pathways in the de-
veloping human brain [12]. Suggested mechanism for the common
neonatal morbidities, including perinatal brain injury, broncho-
pulmonary dysplasia (BPD) and retinopathy of prematurity (ROP), is a
combination of hypoxia, inflammation, infection and oxidative stress
[13,14].
In a multicenter randomized controlled trial, we set out to in-
vestigate whether N‑acetylcysteine (NAC), an antioxidant, precursor of
glutathione and a free radical scavenger [15], decreases these mor-
bidities. The primary outcome measure was BPD defined as oxygen
dependence at an age corresponding to 36 gestational weeks [16]. NAC
is available as a registered drug to treat acetaminophen poisoning, but
it has multiple other uses as well, supported by varying levels of
evidence [17]. Studies of the effects of NAC on various neurological
disorders or brain functions have mostly been carried out in animal
models with only a few studies completed in humans [18]. In rats, NAC
has been demonstrated to improve hippocampal neuronal survival after
transient forebrain ischemia [19] and reduce the infarct area and vo-
lume in a model of experimental stroke [20]. Moreover, it has been
shown to provide substantial neuroprotection against perinatal brain
injury in newborn rats [21]. In human clinical trials, NAC has been
associated with reduced cognitive deficits in patients with probable
Alzheimer's disease [22] and mild traumatic brain injury [23]. In ad-
dition, there is a growing body of literature of potential benefits of NAC
in the treatment of several neuropsychiatric disorders, but many of
these studies require replication and are methodologically preliminary
[24].
The present study is a one-center long-term follow-up investigation
of a Nordic multicenter randomized controlled trial including 391
ELBW infants. The dosage used (16–32 mg/kg/d continuous in-
travenous NAC infusion over 6 days starting before 36 h of age) was
based on a pharmacokinetic study [25]. The control group received a
corresponding placebo infusion with 0.9% sodium chloride. The sets of
vials (10 per infant) to be diluted in glucose and infused were similar
for NAC and placebo and the personnel and researchers were blinded to
the content. There was no benefit of NAC on the primary combined
outcome measure, BPD and death (51 vs 49% in placebo group) [16].
However, there was a slight, but non-significant difference in cystic
periventricular leukomalacia (PVL, 8 vs 11%). This motivated us to
assess whether NAC would decrease more common, less severe
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neurocognitive sequelae and perform a follow-up study in pre-
adolescence. We hypothesized that the postnatal NAC infusion would
decrease the risk of neurocognitive dysfunction.
2. Materials and methods
2.1. Study groups
The randomized, placebo-controlled multicenter trial of ELBW in-
fants on ventilator or nasal continuous positive airway pressure was
conducted in 10 academic intensive care units in Denmark, Finland,
Norway, Sweden and Iceland between 1997 and 2001. In total, 194
infants received NAC and 197 placebo for 6 days [16].
The present study is a follow-up of the infants enrolled in the trial at
the Helsinki University Children's Hospital in Finland (n= 123). Of
these, 103 were alive at the time of the follow-up. Parents of 12 chil-
dren could not be reached; however, for six of these children cognitive
status was known from previous cognitive assessments. One family
declined participation. Thus, the study group in this follow-up assess-
ment consisted of 96 children (Fig. 1).
2.2. Follow-up
2.2.1. Assessment of neurocognition
The children were assessed by a psychologist of the Helsinki
University Children's Hospital or a trained psychology undergraduate,
who were unaware of the patients' treatment assignments in the trial.
General cognitive ability was assessed with a short form of the Finnish
Wechsler Intelligence Scale for Children – third edition (WISC-III) [26].
Three scales were employed: estimated verbal intelligence quotient (IQ;
subtests information, similarities, vocabulary), performance IQ (picture
completion, coding, block design), and the combined full-scale IQ
(FSIQ). Using the original test standardization norms, the scales have a
mean of 100 (SD 15).
The NEPSY-II neuropsychological test battery evaluates cognitive
functioning in six domains [27]. A total of 14 age-appropriate subtests
from five different domains were administered: the attention and ex-
ecutive functions domain (subtests animal sorting, auditory attention
and response set, inhibition); language (comprehension of instructions,
phonological processing, word generation); memory and learning
(memory for designs, narrative memory, word list interference); sen-
sorimotor (imitating hand positions, visuomotor precision); visuospa-
tial processing (arrows, design copying, geometric puzzles). Domain
scores were used in statistical analyses.
Randomization 





Died after treatmentn = 8 (13%)
Lost to follow-up n = 2 (3%)
Lost to follow-up n = 4 (6%)
Declined participation  = 1 (2%)
Participated at 11 years:       





Could not be assessed: 
Intellectual disability n = 2 (4%)1 
Non-Finnish speaker n = 1 (2%) 
WISC-III 
NAC n = 33 
Placebo n = 37 
NEPSY-II
NAC n = 32
Placebo n = 36 
FTF
NAC n = 36 
Placebo n = 40
ATTEX
NAC n = 27
Placebo n = 28
Cognitive assessments
Missing data: 
WISC-III  n = 10 (22%)
NEPSY-II n = 11 (24%) 
FTF   n = 7   (15%) 
ATTEX  n = 16 (35%) 
Questionnaire data
Could not be assessed: 
Intellectual disability n = 5 (10%)2
Missing data:
WISC-III  n = 8   (16%)
NEPSY-II  n = 9   (18%)
FTF   n = 5   (10%)
ATTEX  n = 17 (34%)
Fig. 1. Flow chart of study participation and non-participating children.
1One child additionally had severe cerebral palsy and PVL. 2Two children additionally had cerebral palsy and one had autism.
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2.2.2. Questionnaires
A standardized parental questionnaire (Five to Fifteen, FTF [28,29])
was sent to the families to be completed before the formal assessment.
The questions have been designed to evaluate developmental problems
in children aged five to fifteen years. In this study, 25 items of the
executive functions domain were used, which were compiled into four
subscales according to manual instructions. Lower scores indicate
better outcome.
Another questionnaire was sent to the teachers (The Attention and
Executive Function Rating Inventory, ATTEX [30]). ATTEX is a teacher
rating scale with 55 items in 10 domains describing difficulties of in-
hibition, attention, and executive functions in the school setting. Lower
scores indicate better outcome.
2.2.3. Background data collection and ethics
The perinatal and neonatal data (including grading of the medical
risk factors) was obtained from the initial trial database. In the original
study, intraventricular hemorrhage (IVH) was classified according to
the criteria of Papile et al. [31], PVL according to the criteria of Trounce
et al. [32], necrotizing enterocolitis (NEC) grade III or higher (NEC
needing surgical treatment) according to Bell et al. [33], and ROP
classified as the stage of disease in the more severely affected eye, based
on the International Classification of Retinopathy of Prematurity [34].
Neurological assessment was not carried out in this follow-up study.
The current demographic data was collected from the parents. For the
children who did not participate in the formal neurocognitive assess-
ments, follow-up data was collected from hospital records with parental
permission. Approval to conduct this study was granted by the ethical
committee of the Helsinki University Children's Hospital and the Na-
tional Medical Products Agency. Written informed consent was ob-
tained from the children and their parents.
2.3. Statistical analyses
Background variables were compared using the independent sam-
ples t-test for continuous variables and the exact χ2-test for categorical
data. Group differences in outcome variables were compared using
general linear model. The presented analyses were controlled for sex
and maternal education (divided into 4 classes). An additional analysis
controlled for gestational age (GA), small for gestational age (SGA), IVH
grades 2–4, ROP grades 2–4, NEC grades 3–4 and oxygen dependency at
the age corresponding to 36 gestational weeks (indicator of BPD) was
performed to analyse the effect of these risk factors.
In the neurocognitive data, seven children had 5.0 to 10.0% missing
subtest results; these were estimated with the expectation maximisation
algorithm [35]. The same procedure was used for FTF and ATTEX (1
child with 4.0% and 6 children with 1.8 to 9.1% missing values, re-
spectively). Statistical analyses were performed using IBM SPSS Sta-
tistics 24.0 software (SPSS Inc., Chicago, Illinois, USA). All significance
tests were two-tailed, and p < .05 was considered significant. Partial
eta-squared (ηp2) served as an indicator of effect size.
3. Results
3.1. Study population
The number of deaths in the NAC and placebo groups was 12 (20%)
and 8 (13%) children (Fig. 1), respectively (exact χ2(1) = 1.035,
p= .309). Of the 103 survivors, some cognitive outcome data was
available for 96 (93%) children (46 (94%) in the NAC and 50 (93%) in
the placebo group, exact χ2(1) = 0.067, p= 1.00). The participants
and non-participants were compared with respect to medical risk fac-
tors, but no differences emerged.
There were no statistically significant differences in the background
characteristics or neonatal complications between the participating
children in the treatment groups (Table 1). Of the 96 children, seven
were severely impaired and one did not speak Finnish and could not be
assessed. Families of 16 children declined to participate in the formal
neurocognitive assessment but completed questionnaire data or gave
their permission to collect data from hospital records. In addition, two
children participating in the formal assessment were excluded due to
incomplete testing. Thus, a complete assessment of neurocognition was
obtained in 70 children. Parental and teacher questionnaires were
available for 76 and 55 children, respectively (Fig. 1).
3.2. Cognitive status
We allocated the 96 children with some outcome data into three
outcome groups based on the formal assessment (complete n= 70,
incomplete n= 2) or hospital data (previous neurocognitive assess-
ment, n= 20). If both were missing, the allocation was based on the
FTF questionnaire (whole version, n= 4). All four children allocated
based on the FTF had very few parent-reported developmental pro-
blems, thus their outcome was defined as normal.
1) Normal outcome: FSIQ ≥85, no specific impairments (both verbal
and performance IQ ≥ 70).
2) Mild to moderate dysfunction: FSIQ 70–84, or a specific impairment
(verbal or performance IQ < 70 despite average FSIQ).
3) Severe dysfunction: FSIQ < 70 or a diagnosed severe impairment
(e.g. intellectual disability).
There were no statistically significant differences in cognitive status
between the treatment groups (exact χ2(2) = 0.364, p= .851; Table 2).
3.3. Neurocognitive test performance
Of the 70 children who underwent neurocognitive assessment, there
were no significant differences in general cognitive ability (WISC-III)
between the groups, F(3, 63) = 0.44, p= .726; Wilk's Λ = 0.980,
ηp2 = 0.020. Similarly, in specific neurocognitive skills (NEPSY-II), no
significant group differences were observed, F(5, 58) = 0.60, p= .699;
Table 1












Gestational age (wk) 26.8 (1.8) 26.9 (2.0) .724
Maternal age (y)a 30.4 (5.7) 31.2 (4.5) .444
Boys 21 (46%) 24 (48%) .840
At follow-up
Age at study (y)b 11.4 (1.2) 11.1 (0.9) .203
Maternal educationb .700
Primary school 6 (15%) 4 (9%)
Vocational school 11 (28%) 9 (21%)
Upper secondary school or vocational
college
11 (28%) 14 (33%)
University or university of applied
sciences
12 (30%) 16 (37%)
Risk factors
Small for gestational age 23 (50%) 24 (48%) 1.00
Periventricular leukomalacia 3 (7%) 4 (8%) 1.00
Intraventricular hemorrhage, grade ≥ 2 8 (17%) 8 (16%) 1.00
Necrotizing enterocolitis, grade ≥ 3 7 (15%) 7 (14%) 1.00
Retinopathy of prematurity, grade ≥ 2 19 (41%) 23 (46%) .684
Oxygen dependency at the age
corresponding to 36 gestational weeks
20 (44%) 17 (34%) .403
Values are mean (SD) or n (%).
a Data missing for one child in the NAC group.
b Data not known for 6 children in the NAC and 7 in the control group whose
cognitive status was based on hospital records.
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Wilk's Λ = 0.951, ηp2 = 0.049. For Bonferroni corrected post hoc-ana-
lyses, see Table 3. These results remained after controlling for GA, SGA,
IVH, ROP, NEC and oxygen dependency. None of the risk factors had a
significant impact on the test results.
When comparing the background characteristics of the children
with a complete assessment to the children with data on cognitive
status but who did not participate in the formal assessment, the pro-
portion of children with severe dysfunction in cognitive status and the
prevalence of PVL was significantly higher among the 13 children in the
placebo group who did not participate in the formal assessment than
those 37 who participated (exact χ2(2) = 8.81, p= .020 and exact
χ2(1) = 5.43, p= .049). No differences emerged in the NAC group.
3.4. Parental and teacher evaluations
In parental questionnaires (FTF), there were no significant group
differences in executive functions, F(4, 67) = 0.79, p= .538; Wilk's
Λ = 0.955, ηp2 = 0.045, when controlling for sex and maternal edu-
cation. Similarly, in teacher reports (ATTEX), no significant group dif-
ferences were observed, F(10, 40) = 0.98, p= .476; Wilk's Λ = 0.803,
ηp2 = 0.197. For Bonferroni corrected post hoc-analyses, see Table 3.
However, when controlling for GA, SGA, IVH, ROP, NEC and oxygen
dependency, a main effect of group emerged in ATTEX, F(10,
32) = 2.17, p= .047; Wilk's Λ = 0.596, ηp2 = 0.404, with less symp-
toms of attention and executive dysfunction in the placebo group. In
Bonferroni corrected post hoc tests, the difference was significant in
only one of 10 domains: distractibility (p= .025). Of the risk factors,
ROP had a significant impact on overall test results of the FTF, F(4,
59) = 2.86, p= .031; Wilk's Λ = 0.838, ηp2 = 0.162.
4. Discussion
With the aim to decrease oxidative stress in very preterm infants, we
performed a randomized controlled trial of continuous intravenous in-
fusion of NAC or placebo. In this study of a secondary outcome mea-
sure, neurocognition at 11 years of age, there were no statistically sig-
nificant differences between the treatment arms, except for slightly less
teacher-reported symptoms of distractibility in the placebo group. The
clinical importance of this finding is, however, minimal. This study is
the first trial to assess the long-term benefit of postnatal NAC admin-
istration in ELBW infants.
In experimental animal studies and human clinical trials, potential
neuroprotective effects of NAC have been observed [19–23]. There are
several possible explanations for the contradictory results of this study.
First, the number of studies of the effects of intravenous NAC on chil-
dren is small and, thus, the evidence is limited. Therefore, it is not
known how the immature brain reacts to NAC. In the initial trial, the
change in plasma total cysteine concentration during the NAC infusion
did not differ from that in the placebo infants, which might indicate
that intravenous NAC is poorly deacetylated in preterm infants and so is
unable to act as a glutathione precursor and as an antioxidant [16]. In
addition, the effects of factors in design and implementation of the
initial trial (dosage, timing and duration of intervention) remain un-
clear.
Second, methodological issues in the present study may influence
the results. A possible confounder is linked to the representativeness of
our study groups. In studies of preterm infants, it is common that more
families with low socioeconomic background but also patients with
lower cognitive abilities drop out of studies [36]. In this study, the
cognitive status was not known for the 7 children lost to follow-up or
whose families declined participation. However, among the children
with data on cognitive status but who did not participate in the formal
neurocognitive assessment, there was an over-representation of chil-
dren with adverse cognitive outcome and PVL in the placebo group
among those children who did not participate in formal assessments.
Nevertheless, the cognitive status of the 96 children did not differ be-
tween the NAC and the placebo groups. Hence, we can expect that this
selection effect did not obscure the actual differences in neurocognitive
performance between the study groups.
The strengths of the present study include its randomized, double-
blind, placebo-controlled design. The participation rates among survi-
vors remained high (94% for NAC and 93% for placebo groups) despite
the extended follow-up time. The neurocognitive assessments were
comprehensive and utilised tests that are frequently used in clinical
work. Parental and teacher evaluations of executive functions in home
and school settings provide additional information on possible cogni-
tive deficits. Further, the data records concerning neonatal variables
were systematic and the analyses were adjusted for several confounding
factors.
A limitation of this study is that the sample size was relatively small,
which might not yield enough statistical power; hence, only large effect
sizes would be expected to yield statistically significant differences
between the groups. Since this is the first study to assess the influence of
NAC treatment on cognitive outcome in ELBW children, this will set a
benchmark that possible future studies can use when doing power
analysis and determining sample size. Only children from one partici-
pating center were included in this study, but they represent one third
of all included infants and the standardized assessments could be de-
signed to strictly adhere to the one-center protocol, without problems
arising of regional and language differences. It is unlikely that there
would be a statistically significant difference in neurocognitive test
Table 2






Normal: FSIQ ≥ 85, no specific impairments 33 (72%) 36 (72%)
Mild to moderate dysfunction: FSIQ < 85 or a specific
impairment (verbal or performance IQ < 70)
8 (17%) 7 (14%)
Severe dysfunction: FSIQ < 70 5 (11%) 7 (14%)
Table 3
Mean values (SD) between study groups for all outcome variables from
Bonferroni corrected post hoc-tests.
Test NAC Placebo p
Index/subdomain
General cognitive ability (n= 33) (n= 37)
Verbal IQ 100.1 (17.6) 100.2 (18.8) .985
Performance IQ 80.3 (20.1) 84.0 (21.4) .426
Full-scale IQ 90.0 (15.8) 92.0 (16.8) .601
Specific neurocognitive skills (n= 32) (n= 36)
Executive functions 7.5 (2.1) 8.0 (2.3) .277
Language 8.4 (1.9) 8.6 (2.1) .696
Memory 8.2 (2.4) 7.9 (2.6) .614
Sensorimotor functions 7.6 (2.8) 7.6 (3.0) .939
Visuospatial functions 7.1 (2.4) 7.6 (2.5) .368
Parent report (n= 36) (n= 40)
Attention/concentration 6.8 (5.0) 6.3 (5.3) .690
Overactivity/impulsivity 3.6 (4.1) 3.2 (4.4) .678
Passivity/inactivity 2.3 (1.9) 1.7 (2.0) .134
Planning/organizing 1.8 (1.7) 1.6 (1.8) .579
Teacher report (n= 27) (n= 28)
Distractibility 2.1 (1.8) 1.4 (1.9) .164
Impulsivity 4.3 (4.2) 2.4 (4.5) .113
Motor hyperactivity 1.8 (1.9) 0.8 (2.1) .063
Directing attention 3.0 (2.8) 2.7 (2.9) .717
Sustaining attention 2.6 (3.2) 2.3 (3.4) .694
Shifting attention 1.9 (2.1) 1.8 (2.2) .949
Initiative 2.8 (2.7) 2.3 (2.9) .484
Planning 2.1 (2.0) 1.3 (2.1) .151
Execution of action 3.7 (3.7) 3.1 (3.9) .555
Evaluation 1.5 (1.4) 1.0 (1.5) .211
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performance if all survivors in the different countries were assessed.
Moreover, a small difference in a large sample would not be clinically
relevant for recommending a prophylactic NAC infusion over the first
week of life to all ELBW infants.
5. Conclusion
This is the first randomized controlled trial of postnatal adminis-
tration of NAC in ELBW infants. NAC treatment did not improve neu-
rocognitive functioning in preadolescence. The use of NAC in the neo-
natal care of ELBW children is not justifiable. However, this study sets a
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